Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alexion Pharmaceuticals Inc (NASDAQ:ALXN)

149.61
Delayed Data
As of May 25
 +2.94 / +2.00%
Today’s Change
124.16
Today|||52-Week Range
208.88
-21.57%
Year-to-Date
Frank Sands Sells Visa, Baidu, Alibaba
May 24 / GuruFocus News - Paid Partner Content
Baron Funds Comments on Alexion Pharmaceuticals
May 23 / GuruFocus News - Paid Partner Content
Baron Funds Comments on Alexion Pharmaceuticals
May 23 / GuruFocus News - Paid Partner Content
Pioneer climbs on oil output optimism
Apr 26 / FT.com - Paid Partner Content

Today’s Trading

Previous close146.67
Today’s open146.73
Day’s range146.71 - 150.00
Volume1,395,921
Average volume (3 months)1,721,787
Market cap$32.9B
Dividend yield--
Data as of 05/25/2016

Growth & Valuation

Earnings growth (last year)-79.45%
Earnings growth (this year)+1.34%
Earnings growth (next 5 years)+22.44%
Revenue growth (last year)+12.25%
P/E ratio228.8
Price/Sales16.57
Price/Book4.01

Competitors

 Today’s
change
Today’s
% change
SHPGShire+3.96+2.11%
ZTSZoetis Inc-0.29-0.61%
VRTXVertex Pharmaceutica...+1.14+1.29%
MYLMylan NV+0.24+0.57%
Data as of 05/25/2016

Financials

Next reporting dateJuly 21, 2016
EPS forecast (this quarter)$1.18
Annual revenue (last year)$2.5B
Annual profit (last year)$144.4M
Net profit margin5.81%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
David L. Hallal
Executive Vice President-
Global Operations
Julie O'Neill
Corporate headquarters
Cheshire, Connecticut

Forecasts

Partner Offers

Search for Jobs